TRVI Trevi Therapeutics
- 2.860
- +0.130+4.76%
Trevi Therapeutics News
Buy Rating Affirmed for Trevi Therapeutics Amid Promising Clinical Advances and Solid Financial Position
Analysts Are Bullish on These Healthcare Stocks: MariMed (MRMD), Trevi Therapeutics (TRVI)
Trevi Therapeutics to Participate in Upcoming Conferences
NEW HAVEN, Conn., May 9, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ER) fo
Trevi Therapeutics Price Target Maintained With a $8.00/Share by Needham
Trevi Therapeutics Price Target Maintained With a $8.00/Share by Needham
Analysts Are Bullish on These Healthcare Stocks: Trevi Therapeutics (TRVI), Neurogene (NGNE)
Express News | Trevi Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 GAAP EPS Results
Trevi Therapeutics | 10-Q: Quarterly report
Express News | Trevi Therapeutics Q1 Pretax Profit USD -10.91 Million
Express News | Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Express News | Trevi Therapeutics Q1 Net Income USD -10.902 Million
Express News | Trevi Therapeutics Q1 Operating Expenses USD 11.906 Million
Express News | Trevi Therapeutics Q1 EPS USD -0.11 Vs. Ibes Estimate USD -0.09
Express News | Trevi Therapeutics Q1 Income From Operations USD -11.906 Million Vs. Ibes Estimate USD -9.84 Million
Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024
Conference call and webcast to be held at 4:30 p.m. ETNEW HAVEN, Conn., May 1, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the i
Trevi Therapeutics to Present Phase 2 Results of Haduvio for Chronic Cough at ATS 2024 Conference
Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in idiopathic
Trevi Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/09/2024 155.18% Needham → $8 Reiterates Buy → Buy 03/21/2024 187.08% Oppenheimer $9 → $9 Maintains Outp
CALM,PLAY and VNDA Are Among After Hour Movers
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Oculis Holding (OCS) and Quanterix (QTRX)
Buy Rating for Trevi Therapeutics Anchored on Haduvio's Clinical Promise and Market Potential
Trevi Therapeutics Is Maintained at Outperform by Oppenheimer
Trevi Therapeutics Is Maintained at Outperform by Oppenheimer
Analysis
Price Target
No Data
